CoChat
Sign Up
Cited by 15

MiRNA-501-3p and miRNA-502-3p: a promising biomarker panel for Alzheimer’s disease

Devara, Davin, Sharma, Bhupender, Goyal, Gunjan, Rodarte, Daniela, Kulkarni, Aditi, Tinu, Nathan, Pai, Ayana, Kumar, Subodh·2025·Clinical and Translational Medicine
DOI 10.1002/ctm2.70389PMC PMC12238675

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Introduction: Alzheimer's disease (AD) lacks a less invasive and early detectable biomarker. Here, we investigated the biomarker potential of miR‐501‐3p and miR‐502‐3p using different AD sources. Methods: MiR‐501‐3p and miR‐502‐3p expressions were evaluated in AD cerebrospinal fluid (CSF) exosomes, serum exosomes, familial and sporadic AD fibroblasts and B‐lymphocytes by qRT‐PCR analysis. Further, miR‐501‐3p and miR‐502‐3p expressions were analysed in APP, Tau plasmid transfected cells media exosomes and in different brain cell types. Results: MiR‐501‐3p and miR‐502‐3p expressions were significantly up‐regulated in AD CSF exosomes relative to controls. MiRNA levels were high in accordance with amyloid plaque and NFT density in multiple brain regions. Similarly, both miRNAs were elevated in AD and MCI serum exosomes compared with controls. MiR‐502‐3p expression was high in familial AD and sporadic AD B‐lymphocytes. MiR‐501‐3p and miR‐502‐3p expression were elevated intracellularly and secreted extracellularly in response to APP and Tau pathology. Finally, neurons and astrocytes displayed high expression of these miRNAs. Discussion: These results suggest that miR‐501‐3p and miR‐502‐3p could be promising biomarkers for AD. Key points: MiR‐501‐3p and miR‐502‐3p expression is elevated in AD CSF exosomes, AD serum exosomes, AD B‐lymphocytes and Aβ‐ and Tau‐treated cells. MiR‐501‐3p and miR‐502‐3p are correlated with amyloid plaque and NFT tangle density in specific brain regions. MiR‐501‐3p and miR‐502‐3p are highly expressed in neurons and astrocytes, suggesting that these cells are the source of miRNA secretion. MiR‐501‐3p and miR‐502‐3p could be a promising biomarker panel for AD

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ctm2.70389

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miRNAs expressed in endothelial and neurogenic niches, including miR-126, miR-501-3p, miR-502-3p, and miR-9, implicate post-transcriptional dysfunction in vascular integrity and adult neurogenesis.

    “Furthermore, miRNAs expressed in endothelial and neurogenic niches, including miR-126 (tight-junction stability), miR-501-3p and miR-502-3p (CSF/exosomal biomarkers), and miR-9 (Notch/CAMKK2-regulated neurogenesis and context-dependent amyloid/vascular roles), implicate post-transcriptional dysfunction in vascular integrity and adult neurogenesis, with some mechanisms inferred from vascular injury”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Devara et al., 2025

  • miR-502-3p is part of a plasma and CSF miRNA panel that correlates with amyloid and tau burden in AD patients.

    “Recent exosomal biomarker studies also identify miR-502-3p as part of a plasma and CSF miRNAs panel that correlates with amyloid and tau burden in AD patients (Devara et al., 2025).”

    From Cell-specific MicroRNA networks orchestrate the pathogenesis of Alzheimer’s disease (2026) · cites this paper as Devara et al., 2025

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 63

  1. [2]Khan S, Barve KH, Kumar MS. Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease. Curr Neuropharmacol. 2020; 18(11): 1106‐ 1125. doi: 10.2174/1570159x18666200528142429 32484110 PMC7709159 · DOI · Paper page
  2. [3]Devara D, Choudhary Y, Kumar S. Role of microRNA‐502‐3p in human diseases. Pharmaceuticals (Basel). 2023; 16(4): 532. doi: 10.3390/ph16040532. Published 2023 Apr 2. 37111289 PMC10144852 · DOI
  3. [4]Chen ZR, Huang JB, Yang SL, Hong FF. Role of cholinergic signaling in Alzheimer's disease. Molecules. 2022; 27(6): 1816. doi: 10.3390/molecules27061816. Published 2022 Mar 10. 35335180 PMC8949236 · DOI · Paper page
  4. [5]Comaposada‐Baró R, Benito‐Martínez A, Escribano‐Saiz JJ, et al. Cholinergic neurodegeneration and cholesterol metabolism dysregulation by constitutive p75NTR signaling in the p75exonIII‐KO mice. Front Mol Neurosci. 2023; 16: 1237458. doi: 10.3389/fnmol.2023.1237458. Published 2023 Oct 13. 37900943 PMC10611523 · DOI
  5. [6]Rabins PV, Rovner BW, Rummans T, Schneider LS, Tariot PN. Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Focus (Am Psychiatr Publ). 2017; 15(1): 110‐ 128. doi: 10.1176/appi.focus.15106 31997970 PMC6519627 · DOI
  6. [7]Day GS, Scarmeas N, Dubinsky R, et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: a report of the AAN guidelines subcommittee. Neurology. 2022; 98(15): 619‐ 631. doi: 10.1212/WNL.0000000000200176 35197360 PMC9012273 · DOI
  7. [8]Liu XY, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. World J Stem Cells. 2020; 12(8): 787‐ 802. doi: 10.4252/wjsc.v12.i8.787 32952859 PMC7477654 · DOI
  8. [9]Khan T, Waseem R, Shahid M, et al. Recent advancement in therapeutic strategies for Alzheimer's disease: insights from clinical trials [published online ahead of print, 2023 Oct 31]. Ageing Res Rev. 2023; 92: 102113. doi: 10.1016/j.arr.2023.102113 37918760 · DOI
  9. [10]Gaetani L, Chiasserini D, Paolini Paoletti F, Bellomo G, Parnetti L. Required improvements for cerebrospinal fluid‐based biomarker tests of Alzheimer's disease [published online ahead of print, 2023 Oct 30]. Expert Rev Mol Diagn. 2023; 23(12): 1195‐ 1207. doi: 10.1080/14737159.2023.2276918 37902844 · DOI
  10. [11]Rasmussen J, Langerman H. Alzheimer's disease—why we need early diagnosis. Degener Neurol Neuromuscul Dis. 2019; 9: 123‐ 130. doi: 10.2147/DNND.S228939. Published 2019 Dec 24. 31920420 PMC6935598 · DOI · Paper page
  11. [12]Vijayan M, Kumar S, Bhatti JS, Reddy PH. Molecular links and biomarkers of stroke, vascular dementia, and Alzheimer's disease. Prog Mol Biol Transl Sci. 2017; 146: 95‐ 126. doi: 10.1016/bs.pmbts.2016.12.014 28253992 · DOI
  12. [13]Owen M, Bose N, Nisenbaum L, Partrick KA, Fillit HM. The critical role of biomarkers for drug development targeting the biology of aging. J Prev Alzheimers Dis. 2023; 10(4): 729‐ 742. doi: 10.14283/jpad.2023.111 37874093 · DOI
  13. [14]Kanach C, Blusztajn JK, Fischer A, Delalle I. MicroRNAs as candidate biomarkers for Alzheimer's disease. Noncoding RNA. 2021; 7(1): 8. doi: 10.3390/ncrna7010008. Published 2021 Feb 1. 33535543 PMC7930943 · DOI
  14. [15]Zhao Y, Jaber V, Alexandrov PN, et al. microRNA‐Based Biomarkers in Alzheimer's disease (AD). Front Neurosci. 2020; 14: 585432. doi: 10.3389/fnins.2020.585432 33192270 PMC7664832 · DOI
  15. [16]Siedlecki‐Wullich D, Miñano‐Molina AJ, Rodríguez‐Álvarez J. microRNAs as early biomarkers of Alzheimer's disease: a synaptic perspective. Cells. 2021; 10(1): 113. doi: 10.3390/cells10010113. Published 2021 Jan 9. 33435363 PMC7827653 · DOI · Paper page
  16. [17]Kumar S, Reddy PH. Are circulating microRNAs peripheral biomarkers for Alzheimer's disease?. Biochim Biophys Acta. 2016; 1862(9): 1617‐ 1627. doi: 10.1016/j.bbadis.2016.06.001 27264337 PMC5343750 · DOI
  17. [18]Han YH, Xiang HY, Lee DH, et al. Identification and diagnostic potential of serum microRNAs as biomarkers for early detection of Alzheimer's disease [published online ahead of print, 2023 Nov 1]. Aging (Albany NY). 2023; 15: 12085‐ 12103. doi: 10.18632/aging.205165 37916989 PMC10683584 · DOI
  18. [19]O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018; 9: 402. doi: 10.3389/fendo.2018.00402. Published 2018 Aug 3. 30123182 PMC6085463 · DOI · Paper page
  19. [20]Reddy PH, Williams J, Smith F, et al. MicroRNAs, aging, cellular senescence, and Alzheimer's disease. Prog Mol Biol Transl Sci. 2017; 146: 127‐ 171. doi: 10.1016/bs.pmbts.2016.12.009 28253983 · DOI
  20. [21]Kumar S, Chawla YK, Ghosh S, Chakraborti A. Severity of hepatitis C virus (genotype‐3) infection positively correlates with circulating microRNA‐122 in patients sera. Dis Markers. 2014: 435476. doi: 10.1155/2014/435476 24696531 PMC3948614 · DOI
  21. [22]Kumar S, Vijayan M, Bhatti JS, Reddy PH. MicroRNAs as peripheral biomarkers in aging and age‐related diseases. Prog Mol Biol Transl Sci. 2017; 146: 47‐ 94. doi: 10.1016/bs.pmbts.2016.12.013 28253991 · DOI
  22. [23]Samson JS, Parvathi VD. Prospects of microRNAs as therapeutic biomarkers in non‐small cell lung cancer. Med Oncol. 2023; 40(12): 345. doi: 10.1007/s12032-023-02212-5. Published 2023 Nov 3. 37922117 · DOI
  23. [24]Naithani U, Jain P, Sachan A, Khare P, Gabrani R. MicroRNA as a potential biomarker for systemic lupus erythematosus: pathogenesis and targeted therapy [published online ahead of print, 2023 Nov 3]. Clin Exp Med. 2023; 23(8): 4065‐ 4077. doi: 10.1007/s10238-023-01234-7 37921874 · DOI
  24. [25]Rivera J, Gangwani L, Kumar S. Mitochondria localized microRNAs: an unexplored miRNA niche in Alzheimer's disease and aging. Cells. 2023; 12(5): 742. doi: 10.3390/cells12050742. Published. 36899879 PMC10000969 · DOI
  25. [26]Williams J, Smith F, Kumar S, Vijayan M, Reddy PH. Are microRNAs true sensors of ageing and cellular senescence?. Ageing Res Rev. 2017; 35: 350‐ 363. doi: 10.1016/j.arr.2016.11.008 27903442 PMC5357446 · DOI
  26. [27]Liu S, Fan M, Zheng Q, et al. MicroRNAs in Alzheimer's disease: potential diagnostic markers and therapeutic targets. Biomed Pharmacother. 2022; 148: 112681. doi: 10.1016/j.biopha.2022.112681 35177290 · DOI
  27. [28]Kumar S, Vijayan M, Reddy PH. MicroRNA‐455‐3p as a potential peripheral biomarker for Alzheimer's disease. Hum Mol Genet. 2017; 26(19): 3808‐ 3822. doi: 10.1093/hmg/ddx267 28934394 PMC6075184 · DOI · Paper page
  28. [29]Kumar S, Reddy PH. MicroRNA‐455‐3p as a potential biomarker for Alzheimer's disease: an update. Front Aging Neurosci. 2018; 10: 41. doi: 10.3389/fnagi.2018.00041. Published 2018 Feb 23. 29527164 PMC5829054 · DOI
  29. [30]Kumar S, Reddy AP, Yin X, Reddy PH. Novel microRNA‐455‐3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9): 2428‐ 2440. doi: 10.1016/j.bbadis.2019.06.006 31181293 PMC6688505 · DOI
  30. [32]Kumar S, Reddy PH. Elevated levels of microRNA‐455‐3p in the cerebrospinal fluid of Alzheimer's patients: a potential biomarker for Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(4): 166052. doi: 10.1016/j.bbadis.2020.166052 33412267 PMC7867567 · DOI
  31. [33]Kumar S, Orlov E, Gowda P, et al. Synaptosome microRNAs regulate synapse functions in Alzheimer's disease. NPJ Genom Med. 2022; 7(1): 47. doi: 10.1038/s41525-022-00319-8. Published 2022 Aug 8. 35941185 PMC9359989 · DOI · Paper page
  32. [34]Kumar S. Synaptosome microRNAs: emerging synapse players in aging and Alzheimer's disease. Neural Regen Res. 2023; 18(6): 1275‐ 1276. doi: 10.4103/1673-5374.360172 36453411 PMC9838146 · DOI
  33. [35]Sharma B, Torres MM, Rodriguez S, Gangwani L, Kumar S. MicroRNA‐502‐3p regulates GABAergic synapse function in hippocampal neurons. Neural Regen Res. 2024; 19(12): 2698‐ 2707. doi: 10.4103/NRR.NRR-D-23-01064 38595288 PMC11168514 · DOI
  34. [36]Dalal S, Ramirez‐Gomez J, Sharma B, Devara D, Kumar S. MicroRNAs and synapse turnover in Alzheimer's disease. Ageing Res Rev. 2024; 99: 102377. doi: 10.1016/j.arr.2024.102377 38871301 · DOI
  35. [37]Risha Y, Minic Z, Ghobadloo SM, Berezovski MV. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers. Sci Rep. 2020; 10(1): 13572. doi: 10.1038/s41598-020-70393-4. Published 2020 Aug 11. 32782317 PMC7419295 · DOI
  36. [38]Yang TT, Liu CG, Gao SC, Zhang Y, Wang PC. The serum exosome derived microRNA‐135a, ‐193b, and ‐384 were potential Alzheimer's disease biomarkers. Biomed Environ Sci. 2018; 31(2): 87‐ 96. doi: 10.3967/bes2018.011 29606187 · DOI
  37. [40]Lee JC, Kim SJ, Hong S, Kim Y. Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers. Exp Mol Med. 2019; 51(5): 1‐ 10. doi: 10.1038/s12276-019-0250-2. Published 2019 May 9. PMC6509326 31073121 · DOI · Paper page
  38. [41]Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphoma. Br J Haematol. 2008; 141(5): 672‐ 675. doi: 10.1111/j.1365-2141.2008.07077.x 18318758 · DOI
  39. [42]Condrat CE, Thompson DC, Barbu MG, et al. miRNAs as Biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells; 9(2): 2020. doi: 10.3390/cells9020276. Published 2020 Jan 23. 31979244 PMC7072450 · DOI
  40. [43]Wang J, Chen J, Sen S. MicroRNA as biomarkers and diagnostics. J Cell Physiol. 2016; 231(1): 25‐ 30. doi: 10.1002/jcp.25056 26031493 PMC8776330 · DOI · Paper page
  41. [44]Tribolet L, Kerr E, Cowled C, et al. MicroRNA biomarkers for infectious diseases: from basic research to biosensing. Front Microbiol. 2020; 11: 1197. doi: 10.3389/fmicb.2020.01197. Published 2020 Jun 3. 32582115 PMC7286131 · DOI
  42. [45]Galvão‐Lima LJ, Morais AHF, Valentim RAM, Barreto EJSS. miRNAs as biomarkers for early cancer detection and their application in the development of new diagnostic tools. Biomed Eng Online. 2021; 20(1): 21. doi: 10.1186/s12938-021-00857-9. Published 2021 Feb 16. 33593374 PMC7885381 · DOI
  43. [46]Rivera J, Sharma B, Torres MM, Kumar S. Factors affecting the GABAergic synapse function in Alzheimer's disease: focus on microRNAs. Ageing Res Rev. 2023; 92: 102123. doi: 10.1016/j.arr.2023.102123 37967653 · DOI
  44. [47]Wichmann TO, Damkier HH, Pedersen M. A brief overview of the cerebrospinal fluid system and its implications for brain and spinal cord diseases. Front Hum Neurosci. 2022; 15: 737217. doi: 10.3389/fnhum.2021.737217. Published 2022 Jan 21. 35126070 PMC8813779 · DOI
  45. [48]Pingle SC, Lin F, Anekoji MS, et al. Exploring the role of cerebrospinal fluid as analyte in neurologic disorders. Future Sci OA. 2023; 9(4): FSO851. doi: 10.2144/fsoa-2023-0006. Published 2023 Apr 4. 37090492 PMC10116372 · DOI
  46. [49]Lehmann S, Schraen‐Maschke S, Buée L, et al. Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease. Mol Neurodegener. 2024; 19(1): 66. doi: 10.1186/s13024-024-00755-3. Published 2024 Oct 8. 39380095 PMC11460012 · DOI
  47. [50]Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019; 8(7): 727. doi: 10.3390/cells8070727. Published 2019 Jul 15. 31311206 PMC6678302 · DOI
  48. [51]Irala D, Wang S, Sakers K, et al. Astrocyte‐secreted neurocan controls inhibitory synapse formation and function. Neuron. 2024; 112(10): 1657‐ 1675.e10. doi: 10.1016/j.neuron.2024.03.007 38574730 PMC11098688 · DOI
  49. [52]Igarashi KM. Entorhinal cortex dysfunction in Alzheimer's disease. Trends Neurosci. 2023; 46(2): 124‐ 136. doi: 10.1016/j.tins.2022.11.006 36513524 PMC9877178 · DOI
  50. [53]Hara N, Kikuchi M, Miyashita A, et al. Serum microRNA miR‐501‐3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017; 5(1): 10. doi: 10.1186/s40478-017-0414-z. Published 2017 Jan 31. 28137310 PMC5282710 · DOI
  51. [54]Toyama K, Spin JM, Tsao PS, et al. Serum microRNA‐501‐3p is a potential diagnostic tool for detecting mild cognitive impairment: ehime genome study. J Neurochem. 2023; 166(6): 960‐ 971. 37439367
  52. [55]Krylova SV, Feng D. The machinery of exosomes: biogenesis, release, and uptake. Int J Mol Sci. 2023; 24(2): 1337. doi: 10.3390/ijms24021337. Published 2023 Jan 10. 36674857 PMC9865891 · DOI
  53. [56]Hamdan Y, Mazini L, Malka G. Exosomes and micro‐RNAs in aging process. Biomedicines. 2021; 9(8): 968. doi: 10.3390/biomedicines9080968. Published 2021 Aug 6. 34440172 PMC8393989 · DOI
  54. [57]Yaniv Y, Juhaszova M, Sollott SJ. Age‐related changes of myocardial ATP supply and demand mechanisms. Trends Endocrinol Metab. 2013; 24(10): 495‐ 505. doi: 10.1016/j.tem.2013.06.001 23845538 PMC3783621 · DOI
  55. [58]Zhang C, Rissman RA, Feng J. Characterization of ATP alternations in an Alzheimer's disease transgenic mouse model. J Alzheimers Dis. 2015; 44(2): 375‐ 378. doi: 10.3233/JAD-141890 25261448 PMC4305018 · DOI
  56. [59]Wang MT, Wang YR, Zeng GH, et al. Phenotypic alterations in peripheral blood B lymphocytes of patients with Alzheimer's disease. J Prev Alzheimers Dis. 2025: 100135. doi: 10.1016/j.tjpad.2025.100135 40121165 · DOI
  57. [60]Low YLC, Sun J, Huang X, et al. Profiling peripheral blood lymphocytes in Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. 2025; 20(Suppl 2): e086090. doi: 10.1002/alz.086090 · DOI
  58. [61]Feng W, Zhang Y, Ding S, et al. B lymphocytes ameliorate Alzheimer's disease‐like neuropathology via interleukin‐35. Brain Behav Immun. 2023; 108: 16‐ 31. doi: 10.1016/j.bbi.2022.11.012 36427805 · DOI · Paper page
  59. [62]Trushina E. Alzheimer's disease mechanisms in peripheral cells: promises and challenges. Alzheimers Dement (NY). 2019; 5: 652‐ 660. doi: 10.1016/j.trci.2019.06.008 PMC6838468 31720366 · DOI
  60. [63]Eysert F, Kinoshita PF, Lagarde J, et al. Mitochondrial alterations in fibroblasts from sporadic Alzheimer's disease (AD) patients correlate with AD‐related clinical hallmarks. Acta Neuropathol Commun. 2024; 12(1): 90. doi: 10.1186/s40478-024-01807-x. Published 2024 Jun 8. 38851733 PMC11161956 · DOI
  61. [64]Irala D, Wang S, Sakers K, et al. Astrocyte‐secreted neurocan controls inhibitory synapse formation and function. Neuron. 2024; 112(10): 1657‐ 1675. e10. doi: 10.1016/j.neuron.2024.03.007 38574730 PMC11098688 · DOI
  62. [65]Giacomucci G, Mazzeo S, Bagnoli S, et al. Plasma neurofilament light chain as a biomarker of Alzheimer's disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022; 269(8): 4270‐ 4280. doi: 10.1007/s00415-022-11055-5 35288777 PMC9293849 · DOI
  63. [66]Park SH, Lee EH, Kim HJ, et al. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease. Scientific reports. 2021; 11(1): 13050. doi: 10.1038/s41598-021-92101-6 34158530 PMC8219697 · DOI

Cited by

Sorted by citations

Authors
Devara, D., Sharma, B., Goyal, G., Rodarte, D., Kulkarni, A., Tinu, N., Pai, A., & Kumar, S.
Affiliations
Center of Emphasis in Neuroscience Department of Molecular and Translational Medicine Paul L. Foster School of Medicine Texas Tech University Health Sciences Center El Paso El Paso Texas USA
ORCID
Venue
Clinical and Translational Medicine
Publisher
Wiley
Published
2025-07
Volume
15
Issue
7
ISSN
2001-1326
DOI
10.1002/ctm2.70389
PMC
PMC12238675
Cited by
15
References
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor, 8 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review